Abstract
A 37-yr-old man presented with the classic signs of mineralocorticoid excess hypertension and hypokalemia. The cause was not aldosterone excess, but elevation of plasma 11-deoxycorticosterone (DOC). Computed tomography (CT) scans showed a large right adrenal mass without signs of metastatic disease. The tumor was removed by open laparotomy, and histology revealed an adrenocortical carcinoma. Two yr after diagnosis, the patient is in good general condition and there is no sign of recurrence or metastatic disease, despite the large tumor size. DOC producing adrenocortical carcinomas causing mineralocorticoid hypertension are very rare, so far only 10 cases have been described in the literature.
This is a preview of subscription content, log in via an institution to check access.
References
Stewart PM. Mineralocorticoid hypertension. Lancet 1999, 353: 1341–7.
Biglieri EG. Spectrum of mineralocorticoid hypertension. Hypertension 1991, 17: 251–61.
Biglieri EG, Kater CE. Steroid characteristics of mineralocorticoid adrenocortical hypertension. Clin Chem 1991, 37: 1843–8.
Vecsei P, Abdelhamid S, Mittelstädt GV, Lichtwald K, Haack D, Lewicka S. Aldosterone metabolites and possible aldosterone precursors in hypertension. J Steroid Biochem 1983, 19: 345–51.
Weiss LM. Comparative histologic study of 43 metastatizing and nonmetastazing adrenocortical tumors. Am J Surg Pathol 1984, 8: 163–9.
Powell-Jackson JD, Calin A, Fraser R, et al. Excess deoxycorticosterone secretion from adrenocortical carcinoma. Br Med J 1974, 2: 32–3.
Kelly WF, O’Hare MJ, Loizou S, Davies D, Laing I. Hypermineralocorticism without excessive aldosterone secretion: an adrenal carcinoma producing deoxycorticosterone. Clin Endocrinol (Oxf) 1982, 17: 353–61.
Irony I, Biglieri EG, Perloff D, Rubinoff H. Pathophysiology of deoxycorticosterone-secreting adrenal tumors. J Clin Endocrinol Metab 1987, 65: 836–40.
Makino K, Yasuda K, Okuyama M, Ojima M, Sasano N, Miura K. An adrenocortical tumor secreting weak mineralocorticoids. Endocrinol Jpn 1987, 34: 65–72.
Furuse H, Watase H, Ihara H, et al. Deoxycorticosteroneproducing adrenocortical carcinoma — a case report. Nippon Hinyokika Gakkai Zasshi 1995, 86: 957–60.
Egoshi K, Masai M, Nagao K, Ito H. 11-Deoxycorticosteroneproducing adrenocortical carcinoma. Urol Int 1998, 61: 251–3.
Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999, 6: 719–26.
Farge D, Chatellier G, Pagny JY, Jeunemaitre X, Plouin PF, Corvol P. Isolated clinical syndrome of primary aldosteronism in four patients with adrenocortical carcinoma. Am J Med 1987, 83: 635–40.
Harrison LE, Gaudin PB, Brennan MF. Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 1999, 134: 181–5.
Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992, 112: 963–70.
Weiss LM, Medeiros LJ, Vickery AL. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 1989, 13: 202–6.
Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg 2001, 25: 891–7.
Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990, 322: 1195–201.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Müssig, K., Wehrmann, M., Horger, M. et al. Adrenocortical carcinoma producing 11-deoxycorticosterone: A rare cause of mineralocorticoid hypertension. J Endocrinol Invest 28, 61–65 (2005). https://doi.org/10.1007/BF03345531
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03345531